Skip to main content
MJH Life Sciences
  • Login
  • Register
  • Login
  • Register
Home
  • ONCOLOGY
  • News
  • Blogs
  • Topics
  • Hematology
  • Image IQ
  • Podcasts
  • Videos
  • Slideshows
  • Conferences
MJH Life Sciences

SUBSCRIBE: Print / eNewsletter

SABCS 2012

SABCS: Adjuvant Bevacizumab Fails to Improve Invasive DFS for Triple-Negative Breast Cancer

December 8, 2012
  • Anna Azvolinsky

Triple-negative breast cancer patients with primary invasive cancer did not benefit from adjuvant combination chemotherapy plus bevacizumab compared to chemotherapy alone.

  • READ >>
  • Add new comment

SABCS: Cognitive Impairment in Breast Cancer Patients Begins Even Before Chemo

December 8, 2012
  • Anna Azvolinsky

A small study analyzing neurocognitive function in women undergoing chemotherapy to treat their breast cancer shows that some of the common cognitive issues experienced by breast cancer patients tend to occur not only post-chemotherapy, but also prior to chemotherapy treatment.

  • READ >>
  • Add new comment

SABCS: HDAC Inhibition Sensitizes Triple-Negative Breast Cancer Cells to PARP Inhibition

December 8, 2012
  • Dave Levitan

Combining histone deacetylase (HDAC) inhibitors with PARP inhibitors or cisplatin has the potential to be an effective treatment for triple-negative breast cancer, according to preclinical research presented this week at the San Antonio Breast Cancer Symposium.

  • READ >>
  • Add new comment

SABCS: Novel Agent Added to Letrozole Improves Outcomes in ER-Positive Breast Cancer

December 8, 2012
  • Dave Levitan

Combining an investigational agent called PD 0332991 with letrozole improved progression-free survival over letrozole alone in women with advanced estrogen receptor-positive breast cancer, according to a study presented at the San Antonio Breast Cancer Symposium this week.

  • READ >>
  • Add new comment

SABCS: Neoadjuvant Chemo May Benefit Young Breast Cancer Patients More

December 7, 2012
  • Anna Azvolinsky

Breast cancer patients 35 years and younger, even those with luminal-like disease, derive more benefit from neoadjuvant chemotherapy than do older patients, according to a German study presented at SABCS.

  • READ >>
  • Add new comment

SABCS: Increasing Fulvestrant Dose in Advanced ER-Positive Breast Cancer Yields Better Survival, Similar Toxicity

December 7, 2012
  • Dave Levitan

Increasing the dose of fulvestrant from 250 mg to 500 mg yielded a longer median overall survival as well as a lower overall risk of death in women with locally advanced or metastatic estrogen receptor-positive breast cancer, according to results from the CONFIRM trial.

  • READ >>
  • Add new comment

SABCS: Black Women Less Likely to Undergo Sentinel Lymph Node Biopsy

December 6, 2012
  • Dave Levitan

A large cohort study found that black women with early-stage invasive breast cancer were significantly less likely than white patients to undergo the less invasive axillary sentinel lymph node biopsy. Black women also had a higher rate of lymphedema, due largely to that difference in treatment modalities.

  • READ >>
  • Add new comment

SABCS: Extending Tamoxifen Therapy for Breast Cancer Improves Survival

December 5, 2012
  • Anna Azvolinsky

Patients who took tamoxifen as adjuvant therapy for ER-positive breast cancer for 10 years had both a reduced risk of recurrence and better overall survival compared to patients who stopped after 5 years, according to results of the ATLAS study presented at SABCS.

  • READ >>
  • Add new comment

SABCS: Using Molecular Assays for Breast Cancer in the Clinic

December 4, 2012
  • Antonio C. Wolff, MD, FACP

To kick off SABCS 2012, we discuss the use of molecular testing for the diagnosis and treatment of breast cancer patients in the clinical setting with Dr. Antonio Wolff of the Kimmel Cancer Center at Johns Hopkins University, one of the presenter's during the "Practical Use of Molecular Profiling" session at this year's symposium.

  • READ >>
  • Add new comment

Resource Topics rightRail

  • Resource Topics
  • Partner Content
  • Breast Cancer
  • Acute Myeloid Leukemia
  • HER2-Positive Breast Cancer
  • Videos Breast Cancer
  • Follicular Lymphoma
Cutaneous T-Cell Lymphomas: Mycosis Fungoides and Sézary Syndrome
3 Keys to Success in the Oncology Care Model

Current Issue

ONCOLOGY Vol 33 No 11
Nov 21, 2019 Vol 33 No 11
Subscribe
Connect with Us
  • Column 1
    • Home
    • About Us
    • Contact Us
  • Column 2
    • Editorial Info
    • Editorial Board
  • Column 3
    • Advertising Info
    • Reprints
    • Advertising Terms
  • Column 4
    • Terms of Use
    • Privacy Policy
Modern Medicine Network
© UBM 2019, All rights reserved.
Reproduction in whole or in part is prohibited.

We've noticed that you're using an ad blocker

Our content is brought to you free of charge because of the support of our advertisers. To continue enjoying our content, please turn off your ad blocker.

It's off now Dismiss How do I disable my ad blocker?
❌

How to disable your ad blocker for our site:

Adblock / Adblock Plus
  • Click on the AdBlock / AdBlock Plus icon on the top right of your browser.
  • Click “Don’t run on pages on this domain.” OR “Enabled on this site.”
  • Close this help box and click "It's off now".
Firefox Tracking Prevention
  • If you are Private Browsing in Firefox, "Tracking Protection" may casue the adblock notice to show. It can be temporarily disabled by clicking the "shield" icon in the address bar.
  • Close this help box and click "It's off now".
Ghostery
  • Click the Ghostery icon on your browser.
  • In Ghostery versions < 6.0 click “Whitelist site.” in version 6.0 click “Trust site.”
  • Close this help box and click "It's off now".
uBlock / uBlock Origin
  • Click the uBlock / uBlock Origin icon on your browser.
  • Click the “power” button in the menu that appears to whitelist the current website
  • Close this help box and click "It's off now".